NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
7,496
6,500
0
0
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
42,701
82,288
49,615
47,994
Selling General and Administrative
55,527
41,743
29,472
13,436
Total Operating Expenses
95,779
120,875
73,768
55,047
Operating Income or Loss
-88,298
-114,375
-73,768
-55,047
Interest Expense
2,626
133
43
75
Total Other Income/Expenses Net
16
-272
492
-783
Income Before Tax
-90,722
-114,731
-73,001
-55,562
Income Tax Expense
-178
49
1,355
-672
Income from Continuing Operations
-90,544
-114,780
-74,356
-54,890
Net Income
-90,544
-114,780
-74,356
-54,890
Net Income available to common shareholders
-90,544
-114,780
-74,356
-54,890
Reported EPS
Basic
-
-2.26
-2.49
-2.56
Diluted
-
-2.26
-2.49
-2.56
Weighted average shares outstanding
Basic
-
50,796
29,831
21,478
Diluted
-
50,796
29,831
21,478
EBITDA
-
-114,088
-72,526
-55,254